使用 APCEDEN（基于树突状细胞的疫苗）使口咽罕见腺癌完全缓解：一例病例报告。
Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN (dendritic cell-based vaccine): a case report.
作者信息
Kumar Chaitanya, Kohli Sakshi, Chiliveru Srikanth, Jain Minish, Sharan Bandana
机构信息
R&D APAC Biotech Pvt Ltd Gurgaon India.
Medical Oncology Ruby Hall Clinic Pune India.
出版信息
Clin Case Rep. 2017 Sep 7;5(10):1692-1696. doi: 10.1002/ccr3.1169. eCollection 2017 Oct.
Abstract
APCEDEN is an autologous monocyte-derived dendritic cell-based immunotherapy. A 58-year-old man with adenocarcinoma of oropharynx shows complete remission after receiving APCEDEN in conjunction with Geftinib validated by reduction in size, whereas Gefitinib alone lead to disease progression.
摘要
APCEDEN是一种基于自体单核细胞衍生树突状细胞的免疫疗法。一名58岁的口咽腺癌男性患者在接受APCEDEN联合吉非替尼治疗后，肿瘤大小缩小，显示出完全缓解，而单独使用吉非替尼则导致疾病进展。
Zotero 插件